U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT06926634) titled 'Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)' on April 10.
Brief Summary: The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.
Study Start Date: July 31, 2025
Study Type: INTERVENTIONAL
Condition:
High Grade Neuroendocrine Neoplasms
Intervention:
DRUG: Zanzalintinib
Provided by Exelixis
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Washington University School of Medicine
Published by HT Digital Content Services with permission from Health Dail...